

Brief Report

Incomplete endothelialisation of an Amplatzer Septal Occluder device followed by meningitis and late acute bacterial endocarditis

Jacek Białkowski,¹ Szymon Pawlak,² Paweł Banaszak¹

¹Department of Congenital Heart Diseases and Pediatric Cardiology; ²Department of Transplantology and Cardiac Surgery, Silesian Center for Heart Diseases, Medical University of Silesia, Zabrze, Poland

Abstract A 19-year-old woman with atrial septal defect treated percutaneously with an Amplatzer Septal Occluder 24 months earlier, who presented with a history of bacterial meningitis, was admitted with a diagnosis of endocarditis. After 6 weeks of treatment with antibiotics, the incompletely endothelialised occluder was surgically removed. The present report illustrates the need for long-term follow-up of patients who have received nitinol wire mesh occluders.

Keywords: Amplatzer Septal Occluder; bacterial endocarditis; incomplete endothelialisation

Received: 11 June 2015; Accepted: 28 September 2015; First published online: 28 December 2015

THE AMPLATZER SEPTAL OCCLUDER IS ONE OF THE most frequently used percutaneous devices for the closure of atrial septal defect type II – secundum atrial septal defect. Complications of this procedure include device embolisation/malposition, arrhythmias, cardiac perforation, thrombus formation, and device erosion, with infection being the least common.^{1,2} Late bacterial endocarditis after Amplatzer Septal Occluder treatment has been reported rarely.^{3–5} We describe a case of incomplete endothelialisation of an Amplatzer Septal Occluder device followed by meningitis and late acute bacterial endocarditis in a young woman.

Case description

A 17-year-old girl with a history of moderate-sized secundum atrial septal defect underwent transcatheter closure with a 24-mm Amplatzer Septal Occluder device (ASO-AGA Medical Corporation, Golden Valley, Minnesota, United States of America). The stretch diameter of the atrial septal defect was

24 mm, and there was no residual shunt after implantation. Approximately 24 months later, the patient was admitted to the Infectious Disease Department with symptoms of acute bacterial meningitis, such as unconsciousness, headache, vomiting, and nuchal rigidity, confirmed by lumbar puncture. Antibiotics treatment with ceftriaxon, ampicillin, metronidazol, and fluconazol was initiated. Owing to the positive blood culture for *Staphylococcus aureus*, vancomycin was introduced. Significant clinical improvement was achieved within a few days. In the transthoracic echocardiogram, a mobile echogenic mass (14 × 7 mm) suggestive of vegetation/infected thrombus in the left atrial surface of the device was observed (Fig 1). Low molecular weight heparin was included to the therapy. The patient in a stable condition was transferred to our centre. Antibiotics and low molecular weight heparin therapy were continued. In the following echocardiography examinations, the vegetation disappeared but moderate mitral regurgitation with prolapse of the posterior leaflet appeared. After normalisation of acute biochemical infection markers, the patient was operated. The device was removed, the atrial septal defect was closed with a pericardial patch, and mitral valvuloplasty in the basal part of the posterior leaflet was performed. In the removed device, there was a lack of

Correspondence to: P. Banaszak, Department of Congenital Heart Diseases and Pediatric Cardiology, Silesian Center for Heart Diseases, Medical University of Silesia, Curie-Skłodowskiej 9, 41-800 Zabrze, Poland. Tel/Fax: +48 32 2713401; E-mail: rhplus@op.pl




Figure 1.
 Transthoracic echocardiographic image in the parasternal long-axis plane showing the device (bigger arrow), parallel to the mitral valve vegetation starting from the lower ridge of the left atrial device disc (smaller arrow).




Figure 2.
 Explanted Amplatzer septal occluder device 2 years after implantation showing incomplete endothelialisation of the device.

endothelialisation signs in the peripheral parts of the device and the left hub (Fig 2). The post-surgical course was uneventful. In the echocardiographic examination, only a trivial mitral regurgitation was seen. At 1 month follow-up, the patient remained in good condition, without any additional complications.

Comment

Device infection may occur in two ways: either through introduction of microbes during the procedure or secondary to seeding of microorganisms at a later time. After device implantation, it is assumed

that it takes 6 months for complete endothelialisation, which reduces the risk of infective endocarditis.⁶ Nevertheless, if one counts the reported incidence of bacterial endocarditis with respect to the number of implanted devices, it may show an even lower incidence compared with the incidence within the general population.

The diagnosis of meningitis was established in our patient because of suggestive neurological symptoms. It is impossible to exclude that endocarditis was the underlying neuroinfection, especially when considering the fact that the young, healthy woman had no obvious reason for streptococcal meningitis; however, the patient had an incomplete implant endothelialisation, and this could have been a risk factor for endocarditis.

In cases described in the literature thus far, late endocarditis after Amplatzer Septal Occluder application appears both in children and adults. In our case, it was present in a 19-year-old woman without any additional co-morbidity 2 years after Amplatzer Septal Occluder implantation. We found in the literature three similar cases of late bacterial endocarditis. Slesnick et al³ presented a 4-year-old child with mitral valve prolapse with endocarditis appearing 12 months after Amplatzer Septal Occluder placement. Zahr et al described a 66-year-old man with extended co-morbidity and endocarditis 30 months after the procedure. Aruni et al in another publication reported a 59-year-old man with congestive heart failure and an implanted cardioverter defibrillator. Time of appearance of late endocarditis was not mentioned precisely (probably years).^{4,5} In two studies, it was mentioned that devices were removed surgically and poor endothelialisation was observed in both, as in our case.^{4,6} If delayed or missing endothelialisation may play a key role in these cases, one could speculate it in two ways. The incidence of partial misendothelialisation must be very low among the implanted devices, otherwise a higher endocarditis rate should be found or the missing endothelialisation may be only a co-factor of endocarditis.

Another problem was the infective endocarditis in Amplatzer Septal Occluder that presented shortly, <6 months, after the procedure.^{7,8} The latter emphasises the significance of aseptic precautions during cardiac catheterisation and interventional procedures.

No human studies defining the endothelialisation of Amplatzer Septal Occluder devices exist. Considering worldwide acceptance and increasing utilisation of nitinol wire mesh occluders, certain number of patients with delayed endothelialisation should be expected. They might be at risk of late infectious complications.

A 6-month-long bacterial endocarditis prophylaxis dedicated for patients after device implantation was

arbitrarily determined, and that treatment schedule has been continued as standard of care. The above-mentioned singular cases of late endocarditis after implantation of an Amplatzer Septal Occluder device illustrate the need for long-term follow-up of patients who have received nitinol wire mesh occluders, as well as an increased level of suspicion for device complications if these patients present with septic or embolic phenomenon. It is not proven whether a prolongation of the prophylaxis may have avoided the described endocarditis episode. These rare incidences may not influence the recommendation for endocarditis prophylaxis after device implantation.

We present the following conclusions:

- In any patient with a septal occluder and generalised infection, transthoracic echocardiography or in doubtful cases transoesophageal echocardiography should be performed as soon as possible to exclude endocarditis.
- In our opinion, surgical removal of the device is mandatory in such cases.

Acknowledgements

None.

Financial Support

This research received no specific grant from any funding agency, commercial, or not-for profit sectors.

Conflicts of Interest

None.

References

1. Masura J, Gavora P, Podnar T. Long-term outcome of transcatheter secundum-type atrial septal closure using Amplatzer septal occluders. *J Am Coll Cardiol* 2005; 45: 505–507.
2. Majunke N, Bialkowski J, Wilson N, et al. Closure of atrial septal defect with the Amplatzer septal occluder in adults. *Am J Cardiol* 2009; 103: 550–554.
3. Slesnick T, Neugent AW, Fraser CD, Cannon BC. Incomplete endothelialization and late development of acute bacterial endocarditis after implantation of an Amplatzer septal occluder device. *Circulation* 2008; 117: e326–e327.
4. Zahr F, Katz WE, Toyoda Y, Anderson WD. Late bacterial endocarditis of an Amplatzer septal defect occluder device. *Am J Cardiol* 2010; 105: 279–280.
5. Aruni B, Sharifian A, Herrera CJ. Late bacterial endocarditis of an Amplatzer atrial septal device. *Indian Heart J* 2013; 65: 450–451.
6. Wilson W, Taubert KA, Gewitz M, et al. AHA guideline prevention of infective endocarditis guidelines from American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesiology, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation* 2007; 116: 1736–1754.
7. Balasundaram RP, Anandaraja S, Juneja R, Choudhary SK. Infective endocarditis following implantation of Amplatzer atrial septal occluder. *Indian Heart J* 2005; 57: 167–169.
8. Bullock AM, Menahem S, Wilkinson JL. Infective endocarditis on an occluder closing an atrial septal defect. *Cardiol Young* 1999; 9: 65–67.